Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$27.61 +3.9%	$20.61	$16.10 ▼ $41.94	$3.49B	0.78	2.31 million shs	1.03 million shs
MLTX MoonLake Immunotherapeutics	$54.11 -0.1%	$50.07	$31.42 ▼ $58.26	$3.48B	1.27	475,300 shs	384,559 shs
PGEN Precigen	$3.64 +13.2%	$1.78	$0.65 ▼ $3.90	$1.08B	1.87	3.48 million shs	20.69 million shs
PTGX Protagonist Therapeutics	$56.00 -0.4%	$54.13	$33.31 ▼ $60.60	$3.48B	2.33	929,056 shs	351,825 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	-0.37%	0.00%	+37.86%	+49.49%	-31.76%
MLTX MoonLake Immunotherapeutics	+2.81%	-2.71%	+1.06%	+40.59%	+9.40%
PGEN Precigen	-0.31%	+68.06%	+75.41%	+130.94%	+184.07%
PTGX Protagonist Therapeutics	-0.04%	-0.86%	+1.83%	+22.48%	+35.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLS Apellis Pharmaceuticals	4.5202 of 5 stars	4.3	1.0	4.4	3.3	2.5	0.6
MLTX MoonLake Immunotherapeutics	1.5903 of 5 stars	3.4	1.0	0.0	1.0	2.5	0.0
PGEN Precigen	3.865 of 5 stars	3.4	0.0	4.7	3.1	1.7	0.6
PTGX Protagonist Therapeutics	1.976 of 5 stars	2.5	3.0	0.0	3.1	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.58	Moderate Buy	$34.12	25.09% Upside
MLTX MoonLake Immunotherapeutics	2.78	Moderate Buy	$74.43	36.61% Upside
PGEN Precigen	2.80	Moderate Buy	$8.25	126.52% Upside
PTGX Protagonist Therapeutics	3.00	Buy	$67.20	20.06% Upside

Current Analyst Ratings Breakdown

Latest PGEN, PTGX, APLS, and MLTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	PGEN Precigen	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/19/2025	PGEN Precigen	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$6.00 ➝ $8.00
8/19/2025	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.50
8/15/2025	PGEN Precigen	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underweight ➝ Neutral
8/13/2025	PGEN Precigen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
8/7/2025	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	PTGX Protagonist Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$67.00 ➝ $69.00
8/6/2025	MLTX MoonLake Immunotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$74.00 ➝ $82.00
8/4/2025	APLS Apellis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$35.00 ➝ $37.00
8/1/2025	APLS Apellis Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$17.00 ➝ $19.00
8/1/2025	APLS Apellis Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$39.00 ➝ $40.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$781.37M	4.41	N/A	N/A	$1.24 per share	22.00
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$5.57 per share	N/A
PGEN Precigen	$4.34M	250.05	N/A	N/A	($0.12) per share	-30.35
PTGX Protagonist Therapeutics	$434.43M	8.01	$4.50 per share	12.45	$10.74 per share	5.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	-$197.88M	-$1.82	N/A	N/A	N/A	-30.24%	-116.09%	-26.72%	11/4/2025 (Estimated)
MLTX MoonLake Immunotherapeutics	-$118.94M	-$2.78	N/A	N/A	N/A	N/A	-40.98%	-35.81%	11/6/2025 (Estimated)
PGEN Precigen	-$126.24M	-$0.42	N/A	N/A	N/A	-2,868.66%	-842.83%	-78.98%	N/A
PTGX Protagonist Therapeutics	$275.19M	$0.70	80.10	N/A	N/A	24.88%	8.12%	7.41%	11/6/2025 (Estimated)

Latest PGEN, PTGX, APLS, and MLTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	PGEN Precigen	-$0.14	-$0.11	+$0.03	-$0.09	$0.67 million	$0.86 million
8/6/2025	Q2 2025	PTGX Protagonist Therapeutics	-$0.53	-$0.55	-$0.02	-$0.55	$8.32 million	$5.55 million
8/5/2025	Q2 2025	MLTX MoonLake Immunotherapeutics	-$0.73	-$0.87	-$0.14	-$0.87	N/A	N/A
7/31/2025	Q2 2025	APLS Apellis Pharmaceuticals	-$0.44	-$0.33	+$0.11	-$0.33	$187.91 million	$171.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	2.90	3.77	3.16
MLTX MoonLake Immunotherapeutics	0.21	16.65	16.65
PGEN Precigen	N/A	2.71	2.71
PTGX Protagonist Therapeutics	N/A	16.97	16.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
MLTX MoonLake Immunotherapeutics	93.85%
PGEN Precigen	33.51%
PTGX Protagonist Therapeutics	98.63%

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.50%
MLTX MoonLake Immunotherapeutics	12.02%
PGEN Precigen	47.10%
PTGX Protagonist Therapeutics	4.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	126.29 million	118.08 million	Optionable
MLTX MoonLake Immunotherapeutics	2	64.23 million	56.51 million	Optionable
PGEN Precigen	190	297.97 million	157.63 million	Optionable
PTGX Protagonist Therapeutics	120	62.21 million	59.16 million	Optionable

PGEN, PTGX, APLS, and MLTX Headlines

Recent News About These Companies

Invesco Ltd. Has $41.57 Million Position in Protagonist Therapeutics, Inc. $PTGX

August 20 at 3:42 AM | marketbeat.com

Deutsche Bank AG Has $3.18 Million Holdings in Protagonist Therapeutics, Inc. $PTGX

August 20 at 3:24 AM | marketbeat.com

E Fund Management Co. Ltd. Sells 71,950 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

August 18 at 5:10 AM | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by Public Sector Pension Investment Board

August 15, 2025 | marketbeat.com

Informed Momentum Co LLC Takes Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

August 13, 2025 | marketbeat.com

Knott David M Jr Purchases 23,632 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

August 12, 2025 | marketbeat.com

Does Protagonist Therapeutics’ (PTGX) Widening Loss and Shelf Registration Signal a Strategic Pivot?

August 12, 2025 | finance.yahoo.com

Wedbush Issues Optimistic Estimate for PTGX Earnings

August 12, 2025 | americanbankingnews.com

Wedbush Has Positive Estimate for PTGX Q3 Earnings

August 11, 2025 | marketbeat.com

Wedbush Expects Higher Earnings for Protagonist Therapeutics

August 9, 2025 | marketbeat.com

7PTGX : What 4 Analyst Ratings Have To Say About Protagonist...

August 8, 2025 | benzinga.com

JMP Securities Forecasts Strong Price Appreciation for Protagonist Therapeutics (NASDAQ:PTGX) Stock

August 8, 2025 | marketbeat.com

Protagonist Therapeutics files automatic mixed securities shelf

August 7, 2025 | msn.com

Protagonist (PTGX) Q2 Revenue Falls 26%

August 7, 2025 | fool.com

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2025 | zacks.com

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 6, 2025 | accessnewswire.comA

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Holdings Raised by XTX Topco Ltd

August 5, 2025 | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Average Rating of "Buy" by Analysts

August 4, 2025 | marketbeat.com

Jupiter Asset Management Ltd. Makes New $8.13 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

August 4, 2025 | marketbeat.com

GSA Capital Partners LLP Acquires New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

August 4, 2025 | marketbeat.com

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Holdings Raised by Envestnet Asset Management Inc.

August 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PGEN, PTGX, APLS, and MLTX Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

$27.61 +1.03 (+3.86%)

Closing price 03:59 PM Eastern

Extended Trading

$27.54 -0.07 (-0.25%)

As of 04:10 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

MoonLake Immunotherapeutics NASDAQ:MLTX

$54.11 -0.03 (-0.06%)

Closing price 03:59 PM Eastern

Extended Trading

$54.14 +0.04 (+0.06%)

As of 04:10 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Precigen NASDAQ:PGEN

$3.64 +0.43 (+13.24%)

Closing price 03:59 PM Eastern

Extended Trading

$3.68 +0.05 (+1.24%)

As of 04:17 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Protagonist Therapeutics NASDAQ:PTGX

$56.00 -0.23 (-0.42%)

Closing price 03:59 PM Eastern

Extended Trading

$56.00 +0.00 (+0.01%)

As of 04:10 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time